The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue)
The purpose of this Notice of Special Interest is to inform potential applicants to the National Heart, Lung and Blood Institute (NHLBI) of an area of special interest in exploring bold, new bioengineering approaches or concepts, including computationally-efficient methods, that are important to a substantive heart, lung, blood or sleep area, and in supporting the early phases of these innovative bioengineering projects which are, in turn, expected to transition into research to translate them into practice, technologies, or commercial products.
This Notice of Special Interest (NOSI) invites research applications that propose short-term, exploratory bioengineering studies. The exploratory nature of the R21 mechanism is meant to foster discovery- and design-driven bioengineering research ideas that are important across the Institute and that are critical for future hypothesis-generating projects. It is noteworthy that this program emphasizes development rather than efficacy of first-generation prototypes. The NHLBI is interested in the development of highly innovative or “blue sky” ideas for diagnostics, therapeutics, surgical technologies, computational modeling tools, smart biomaterials for self-adjusting implants, and nanotechnologies, as applied to the mission areas of the Institute.
Long-term projects, or projects designed to increase knowledge in a well-established area, will not be considered for R21 awards. Applications proposing to conduct clinical trials are not appropriate for this NOSI. Applicants who already have first-generation prototypes, new processes of proven feasibility, or applications proposing to validate highly innovative strategies for creating new animal models are not responsive to this announcement, but should consider applying for support under the NHLBI Catalyze Program, which plans to release funding announcements in FY2019 and FY2020. Overviews of the Catalyze program initiatives can be found at: https://www.nhlbi.nih.gov/events/2018/national-heart-lung-and-blood-advisory-council-june-2018-meeting-summary.
Applications in response to this NOSI must be submitted using the following target opportunity or subsequent reissued equivalent.
- PA-20-195- NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
Applications will be accepted through July 16, 2021 by 5:00 PM local time of the applicant organization. Any applications submitted in response to this NOSI received on or after the expiration date of July 16, 2021 will be withdrawn.